Skip Navigation

European Heart Journal 1995 16(2):171-176;
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by SCHULTE, K.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SCHULTE, K.-L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

24 h anti-anginal and anti-ischaemic effects with once daily felodipine

A double-blind comparison with nifedipine, twice daily, and placebo in patients with stable exercise induced angina pectoris

K.-L. SCHULTE

I. Department of Internal Medicine, Charité, Humboldt University Berlin, Germany

Received 21 February 1994; revised 7 July 1994; accepted 10 August 1994.

Correspondence: Professor K.-L. Schulte, I. Department of Internal Medicine, Division of Angiology, Chanté, Humboldt-University, Schumannstr. 20/21, D-I0098 Berlin, Germany.

Abstract

The effects, as monotherapy, of felodipine ER 10 mg o.m. and nifedipine SR 20 mg b.d. were compared in a double-blind, randomized, placebo-controlled, three-way cross-over trial in 43 patients with stable exercise-induced angina pectoris. The exercise tests were performed at the end of dosage interval (i.e. 24 h after felodipine ER, 12 h after nifedipine SR) and at the expected peak time of 3 h post dose.

Felodipine and nifedipine improved exercise duration by 66 and 50 s, respectively, (P<0.001) compared with placebo at the end of the dosing interval. Time to the end of exercise showed no statistically significant difference between the two calcium antagonists. The onset of anginal pain and time to 1 mm ST depression were significantly more delayed by felodipine ER than nifedipine SR (22 s and 19 s, respectively, P<0.05). Both felodipine and nifedipine decreased the pain score and rate pressure product at the highest comparable work load. Overall tolerability was good for both drugs.

Key Words: Angina pectoris • exercise test • felodipine ER • nifedipine SR • placebo


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
T. Hasegawa, A. Kimura, M. Miyataka, M. Inagaki, and K. Ishikawa
Basic Fibroblast Growth Factor Increases Regional Myocardial Blood Flow and Salvages Myocardium in the Infarct Border Zone in a Rabbit Model of Acute Myocardial Infarction
Angiology, June 1, 1999; 50(6): 487 - 495.
[Abstract] [PDF]

Home page
 JAMAHome page
P. A. Heidenreich, K. M. McDonald, T. Hastie, B. Fadel, V. Hagan, B. K. Lee, and M. A. Hlatky
Meta-analysis of Trials Comparing {beta}-Blockers, Calcium Antagonists, and Nitrates for Stable Angina
JAMA, May 26, 1999; 281(20): 1927 - 1936.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
W. B. Stason, C. H. Schmid, D. Niedzwiecki, G. W. Whiting, J.-F. Caubet, D. Cory, D. Luo, S. D. Ross, and T. C. Chalmers
Safety of Nifedipine in Angina Pectoris : A Meta-Analysis
Hypertension, January 1, 1999; 33(1): 24 - 31.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
M. Miyataka, K. Ishikawa, and R. Katori
Basic Fibroblast Growth Factor Increased Regional Myocardial Blood Flow and Limited Infarct Size of Acutely Infarcted Myocardium in Dogs
Angiology, May 1, 1998; 49(5): 381 - 390.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.